



August 1, 2016

Dear Healthcare Professional,

Moda Health has partnered with Magellan Rx Management (Magellan Rx) to assist you in medical pharmacy management through the provider administered injectable drug program. We are committed to providing our members with access to high-quality healthcare. To ensure our members receive quality and affordable care, we will implement updates to the review and approval processes of certain injectable medications.

Effective October 1, 2016, nine new medications will be added to the prior authorization list of medications currently in the Magellan Rx program.

Magellan Rx will review your prior authorization requests for the following specialty injectable medications, along with other specialty medications that are already part of the program when administered in:

- an outpatient facility
- a patient’s home
- a physician’s office

Brand name	Generic name	HCPCS code
Bendeka	bendamustine	J9999
Cinqair	reslizumab	J3590
Darzalex	daratumumab	J9999
Empliciti	elotuzumab	J9999
Kanuma	sebelipase alfa	J3590/C9478
Nucala	mepolizumab	J3590
Onivyde	irinotecan liposome injection	J9999
Portrazza	necitumumab	J9999
Tecentriq	atezolizumab	J9999

Completing prior authorization requests through Magellan Rx will help expedite claims processing and doesn’t require you to submit medical records. If you don’t obtain a prior authorization, your claims may be delayed or denied until we receive the information needed to establish medical necessity.

To learn more about our injectable drug program, please check out our updated Injectable Drug Program FAQ at modahealth.com/pdfs/faq_injectables.pdf



modahealth.com

PO Box 40384 Portland, Oregon 97240 | 800-852-5195

We appreciate your support in assuring our members receive quality care. If you have any questions, please call our Customer Service team toll-free at 800-258-2037.

Sincerely,

Your Moda Health Provider Relations team